{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T06:37:11Z","timestamp":1756190231626},"reference-count":27,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>A new vaccine against meningitis A was introduced in Africa meningitis belt in 2010. This study was planned to describe the incidence and types of adverse events following immunization (AEFIs) with a new conjugate vaccine against meningitis A (MenAfrivac\u2122) in a Cameroonian vaccination campaign.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The campaign was conducted in Adamawa and North West regions in December 2012 and the AEFIs enhanced surveillance from December 2012 to January 2013. Incidence rates (IR) of overall and serious AEFIs were estimated as well as AEFI incidence rates by type, age group and region. AEFI symptoms were aggregated in System Organ Class (SOC).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 2\u2009093\u2009381 persons vaccinated, 1352 AEFIs were reported. Of these, 228 (16.9%) were excluded because of not meeting inclusion criteria and 1124 (83.1%) included (IR: 53.7\/100\u2009000 doses administered\/8\u2009weeks). Of the 82 serious AEFIs reported, 52 (63.2%) met the case definition. 23 (28.1%) were investigated, of which 4 (17.4%) were probably vaccine product\u2010related reactions (IR: 0.2\/100\u2009000 doses administered\/8\u2009weeks). Fever was the most common reported AEFI with 626 cases (IR: 31.4\/100\u2009000 doses administered\/8\u2009weeks). The proportion of people with the SOC \u201cGastrointestinal disorders\u201d was significantly lower in ages 5\u201315 and 16\u201329 years than 1\u20134 years [aRR\u2009=\u20090.63(0.42\u20130.93) and 0.54(0.36\u20130.81) respectively].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Incidence and types of AEFI reported during MenAfriVac<jats:sup>TM<\/jats:sup> vaccination campaign organized in Cameroon in 2012 did not suggest concern regarding the vaccine safety. Differences in frequency of AEFIs types per age group could guide the monitoring of AEFIs frequency in future campaigns. Efforts are needed to improve the investigation rate of serious AEFIs. Copyright \u00a9 2016 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4027","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T11:09:32Z","timestamp":1463137772000},"page":"1170-1178","source":"Crossref","is-referenced-by-count":5,"title":["Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC\u2122) in Cameroon"],"prefix":"10.1002","volume":"25","author":[{"given":"Jerome","family":"Ateudjieu","sequence":"first","affiliation":[{"name":"Adamawa Health Region and North West Health Region  Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beat","family":"Stoll","sequence":"additional","affiliation":[{"name":"Adamawa Health Region and North West Health Region  Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Nguefack\u2010Tsague","sequence":"additional","affiliation":[{"name":"Adamawa Health Region and North West Health Region  Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin Ndinakie","family":"Yakum","sequence":"additional","affiliation":[{"name":"Adamawa Health Region and North West Health Region  Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcellin Nimpa","family":"Mengouo","sequence":"additional","affiliation":[{"name":"Adamawa Health Region and North West Health Region  Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blaise","family":"Genton","sequence":"additional","affiliation":[{"name":"Adamawa Health Region and North West Health Region  Cameroon"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Global Manual on Surveillance of AEFI. Available at:http:\/\/www.who.int\/vaccine_safety\/publications\/Global_Manual_on_Surveillance_of_AEFI.pdf?ua=1. Accessed October 15 2015."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/853083"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.05.045"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-6-101"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.012"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.02.011"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831050-00003"},{"key":"e_1_2_9_9_1","first-page":"828","article-title":"Vaccinovigilance in Europe\u2014need for timeliness, standardization and resources","volume":"82","author":"Lankinen KS","year":"2004","journal-title":"Bull World Health Organ"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.02.041"},{"key":"e_1_2_9_11_1","unstructured":"MenAfriVac Meningococcal A Conjugate Vaccine. Serum Institute of India Ltd. Available at:http:\/\/www.seruminstitute.com\/content\/products\/product_menafrivac.htm. Accessed October 16 2015."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.19619"},{"key":"e_1_2_9_13_1","unstructured":"Meningitis A vaccine now recommended in routine immunization schedules. Available at:http:\/\/www.afro.who.int\/media\u2010centre\/afro\u2010feature\/item\/7312\u2010meningitis\u2010a\u2010vaccine\u2010now\u2010recommended\u2010in\u2010routine\u2010immunization\u2010schedules.html?lang=en. Accessed October 16 2015."},{"key":"e_1_2_9_14_1","unstructured":"Weekly epidemiological record. Available at:http:\/\/www.who.int\/wer\/2011\/wer8630.pdf. Accessed October 16 2015."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.12.112"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.006"},{"key":"e_1_2_9_17_1","unstructured":"Immunization Safety Surveillance. Guidelines for immunization programme managers on surveillance of adverse events following immunization. Available at:http:\/\/www.wpro.who.int\/topics\/immunization_safety\/ImmunizationSafetySurveillance.pdf. Accessed October 16 2015."},{"key":"e_1_2_9_18_1","series-title":"Advances in Patient Safety","volume-title":"Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology)","author":"Kohl KS","year":"2005"},{"key":"e_1_2_9_19_1","unstructured":"Causality assessment of an adverse event following immunization. User manual for the revised WHO classification. Available at:http:\/\/www.who.int\/vaccine_safety\/publications\/aevi_manual.pdf?ua=1%7C. Accessed October 16 2015."},{"key":"e_1_2_9_20_1","unstructured":"Introductory Guide MedDRA Version 16.1. Available at:http:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_16_1_english.pdf. Accessed October 16 2015."},{"key":"e_1_2_9_21_1","unstructured":"ICH\u2010Endorsed Guide for MedDRA Users on Data Output. Available at:https:\/\/www.meddra.org\/sites\/default\/files\/guidance\/file\/9610\u20101610_datretptc_r3.6_sep2013.pdf. Accessed October 16 2015."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00314-0"},{"key":"e_1_2_9_23_1","unstructured":"Cameroon Ministry of Public Health.Campagne de vaccination contre la m\u00e9ningite \u00e0 M\u00e9ningocoque A par le MenAfriVac. Phase II. R\u00e9gions de l'Adamaoua et du Nord\u2010Ouest Du 03 au 12 D\u00e9cembre 2012 Rapport g\u00e9n\u00e9ral.2013."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003812"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.04.050"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.08.004"},{"key":"e_1_2_9_27_1","unstructured":"R\u00e9publique du Cameroun Enqu\u00eate D\u00e9mographique et de Sant\u00e9 et \u00e0 Indicateurs Multiples (EDS\u2010MICS) 2011 [FR260] \u2010 FR260.pdf. Available at:https:\/\/dhsprogram.com\/pubs\/pdf\/FR260\/FR260.pdf. Accessed October 16 2015."},{"key":"e_1_2_9_28_1","first-page":"294","article-title":"Surveillance of adverse events following immunisation: the model of SAEFVIC, Victoria","volume":"35","author":"Clothier HJ","year":"2011","journal-title":"Commun Dis Intell Q Rep"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.4027","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:08:47Z","timestamp":1696345727000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/pds.4027"],"URL":"https:\/\/doi.org\/10.1002\/pds.4027","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]}}}